Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
IGM Biosciences, Inc. - Common Stock
(NQ:
IGMS
)
1.270
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about IGM Biosciences, Inc. - Common Stock
< Previous
1
2
Next >
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OLO, SPTN, IGMS on Behalf of Shareholders
July 05, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
IGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders
July 01, 2025
From
Halper Sadeh LLC
Via
Business Wire
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
July 01, 2025
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
January 09, 2025
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
November 08, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at Three Upcoming Investor Conferences
November 04, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
September 30, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
September 10, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 14, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the Jefferies Healthcare Conference
May 29, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference
May 07, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Refocusing of Sanofi Collaboration
April 17, 2024
Agreement focuses on immunology/inflammation, aligning with Sanofi’s ongoing commitment to advancing therapies for patients across multiple inflammatory diseases
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
April 10, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 07, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
December 05, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Third Quarter 2023 Financial Results
November 13, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at Two Upcoming Investor Conferences
November 07, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
October 03, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Second Quarter 2023 Financial Results
August 03, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
July 03, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement
June 22, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Announces Proposed Public Offering and Concurrent Private Placement
June 21, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
June 02, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the Jefferies Healthcare Conference
June 01, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis
May 31, 2023
Imvotamab, a CD20 x CD3 bispecific monoclonal antibody, offers potential for deeper B cell depletion than currently approved therapies
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update
May 30, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
